|
|
|
| Research progress of inflammatory biomarkers of diabetic nephropathy#br# |
| FANG Yaxuan ZHONG Ke NI Qingying HE Zhenyang YANG Bo |
| The First Affiliated Hospital of Tianjin University of Chinese Medicine National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300380, China |
|
|
|
Abstract Diabetic nephropathy (DN) is a renal microvascular disease caused by long-term diabetes mellitus (DM), which is also the main cause of end-stage kidney disease. The pathogenesis of DN involves a wide range. Recent studies have shown that inflammation plays a key role in the pathogenesis of DN. Increased expression of cell adhesion molecules, growth factors, chemokines, and pro-inflammatory cytokines is found in the renal tissues of DM patients, which is closely related to renal function injury. Eight inflammatory factors closely related to the pathogenesis of DN, including high sensitivity C-reactive protein, ratio of neutrophil count to lymphocyte count, pentraxin 3, tumor necrosis factor-α and its receptor, interleukins, Nod-like receptor protein 3 inflammasome, adhesion molecule and monocyte chemoattractant protein-1 are discussed in this paper, aiming to provide a new idea for monitoring the renal function changes and early treatment of DM patients.
|
|
|
|
|
|
[1] Cole JB，Florez JC. Genetics of diabetes mellitus and diabetes complications [J]. Nat Rev Nephrol，2020，16（7）：377-390.
[2] Luk AOY，Ke C，Lau ESH，et al. Secular trends in incidence of type 1 and type 2 diabetes in Hong Kong：A retrospective cohort study [J]. PLoS Med，2020，17（2）：e1003052.
[3] Wang M，Gong WW，Pan J，et al. Incidence and Time Trends of Type 2 Diabetes Mellitus among Adults in Zhejiang Province，China，2007-2017 [J]. J Diabetes Res，2020， 2020：2597953.
[4] Lytvyn Y，Bjornstad P，van Raalte DH，et al. The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications [J]. Endocr Rev，2020，41（2）：202-231.
[5] Matoba K，Takeda Y，Nagai Y，et al. Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease [J]. Int J Mol Sci，2019，20（14）：3393.
[6] Tang SCW，Yiu WH. Innate immunity in diabetic kidney disease [J]. Nat Rev Nephrol，2020，16（4）：206-222.
[7] Sinha SK，Nicholas SB，Sung JH，et al. hs-CRP Is Associated With Incident Diabetic Nephropathy：Findings From the Jackson Heart Study [J]. Diabetes Care，2019，42（11）：2083-2089.
[8] Liu F，Chen HY，Huang XR，et al. C-reactive protein promotes diabetic kidney disease in a mouse model of type 1 diabetes [J]. Diabetologia，2011，54（10）：2713-2723.
[9] Chung FM，Tsai JC，Chang DM，et al. Peripheral total and differential leukocyte count in diabetic nephropathy： the relationship of plasma leptin to leukocytosis [J]. Diabetes Care，2005，28（7）：1710-1717.
[10] Azab B，Daoud J，Naeem FB，et al. Neutrophil-to-lymphocyte ratio as a predictor of worsening renal function in diabetic patients （3-year follow-up study）[J]. Ren Fail，2012，34（5）：571-576.
[11] Zhang J，Zhang R，Wang Y，et al. Effects of neutrophil-lymphocyte ratio on renal function and histologic lesions in patients with diabetic nephropathy [J]. Nephrology（Carlton），2019，24（11）：1115-1121.
[12] Rathore M，Girard C，Ohanna M，et al. Cancer cell-derived long pentraxin 3 （PTX3） promotes melanoma migration through a toll-like receptor 4 （TLR4）/NF-κB signaling pathway [J]. Oncogene，2019，38（30）：5873-5889.
[13] Uzun S，Ozari M，Gursu M，et al. Changes in the inflammatory markers with advancing stages of diabetic nephropathy and the role of pentraxin-3 [J]. Ren Fail，2016，38（8）：1193-1198.
[14] Suliman ME，Yilmaz MI，Carrero JJ，et al. Novel links between the long pentraxin 3，endothelial dysfunction，and albuminuria in early and advanced chronic kidney disease [J]. Clin J Am Soc Nephrol，2008，3（4）：976-985.
[15] Fathy SA，Mohamed MR，Ali MAM，et al. Influence of IL-6，IL-10，IFN-γ and TNF-α genetic variants on susceptibility to diabetic kidney disease in type 2 diabetes mellitus patients [J]. Biomarkers，2019，24（1）：43-55.
[16] Kalantarinia K，Awad AS，Siragy HM. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats [J]. Kidney Int，2003，64（4）：1208-1213.
[17] Cao L，Boston A，Jegede O，et al. Inflammation and Kidney Injury in Diabetic African American Men [J]. J Diabetes Res，2019，2019：5359635.
[18] Niewczas MA，Gohda T，Skupien J，et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes [J]. J Am Soc Nephrol，2012，23（3）：507-15.
[19] Ridker PM. Targeting Interleukin-1 and Interleukin-6： The Time Has Come to Aggressively Address Residual Inflammatory Risk [J]. J Am Coll Cardiol，2020，76（15）：1774-1776.
[20] Murakami M，Kamimura D，Hirano T. Pleiotropy and Specificity：Insights from the Interleukin 6 Family of Cytokines [J]. Immunity，2019，50（4）：812-831.
[21] Kang S，Tanaka T，Narazaki M，et al. Targeting Interleukin-6 Signaling in Clinic [J]. Immunity，2019，50（4）：1007-1023.
[22] Choi YH，Lim EJ，Kim SW，et al. IL-27 enhances IL-15/IL-18-mediated activation of human natural killer cells [J]. J Immunother Cancer，2019，7（1）：211.
[23] Lei Y，Devarapu SK，Motrapu M，et al. Interleukin-1β Inhibition for Chronic Kidney Disease in Obese Mice With Type 2 Diabetes [J]. Front Immunol，2019，10：1223.
[24] Sangoi MB，Carvalho JAM，Guarda NS，et al. Association between Urinary Levels of Interleukin-6，Interleukin-10 and Tumor Necrosis Factor-Alpha with Glomerular and Tubular Damage Indicators in Patients with Type 2 Diabetes [J]. Clin Lab，2019，65（11）.
[25] Yaribeygi H，Atkin SL，Sahebkar A. Interleukin-18 and diabetic nephropathy：A review [J]. J Cell Physiol，2019， 234（5）：5674-5682.
[26] Chi K，Geng X，Liu C，et al. Research Progress on the Role of Inflammasomes in Kidney Disease [J]. Mediators Inflamm，2020，2020：8032797.
[27] Fu Y，Wu N，Zhao D. Function of NLRP3 in the Pathogenesis and Development of Diabetic Nephropathy [J]. Med Sci Monit，2017，23：3878-3884.
[28] El-Horany HE，Abd-Ellatif RN，Watany M，et al. NLRP3 expression and urinary HSP72 in relation to biomarkers of inflammation and oxidative stress in diabetic nephropathy patients [J]. IUBMB Life，2017，69（8）：623-630.
[29] Wu M，Han W，Song S，et al. NLRP3 deficiency ameliorates renal inflammation and fibrosis in diabetic mice [J]. Mol Cell Endocrinol，2018，478：115-125.
[30] Garrido W，Jara C，Torres A，et al. Blockade of the Adenosine A3 Receptor Attenuates Caspase 1 Activation in Renal Tubule Epithelial Cells and Decreases Interleukins IL-1β and IL-18 in Diabetic Rats [J]. Int J Mol Sci，2019，20（18）：4531.
[31] Bui TM，Wiesolek HL，Sumagin R. ICAM-1： A master regulator of cellular responses in inflammation，injury resolution，and tumorigenesis [J]. J Leukoc Biol，2020， 108（3）：787-799.
[32] Karimi Z，Kahe F，Jamil A，et al. Intercellular adhesion molecule-1 in diabetic patients with and without microalbuminuria [J]. Diabetes Metab Syndr，2018，12（3）：365-368.
[33] Astrup AS，Tarnow L，Pietraszek L，et al. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years：association with mortality and decline of glomerular filtration rate [J]. Diabetes Care，2008，31（6）：1170-1176.
[34] Al-Rubeaan K，Nawaz SS，Youssef AM，et al. IL-18，VCAM-1 and P-selectin as early biomarkers in normoalbuminuric Type 2 diabetes patients [J]. Biomark Med，2019，13（6）：467-478.
[35] Siddiqui K，Joy SS，Al-Rubeaan K. Association of urinary monocyte chemoattractant protein-1 （MCP-1） and kidney injury molecule-1（KIM-1）with risk factors of diabetic kidney disease in type 2 diabetes patients [J]. Int Urol Nephrol，2019，51（8）：1379-1386.
[36] Fufaa GD，Weil EJ，Nelson RG，et al. CKD Biomarkers Consortium and the RASS Investigators. Urinary monocyte chemoattractant protein-1 and hepcidin and early diabetic nephropathy lesions in type 1 diabetes mellitus [J]. Nephrol Dial Transplant，2015，30（4）：599-606.
[37] Comai G，Malvi D，Angeletti A，et al. Histological Evidence of Diabetic Kidney Disease Precede Clinical Diagnosis [J]. Am J Nephrol，2019，50（1）：29-36.
[38] Sousa GR，Pober D，Galderisi A，et al. Glycemic Control，Cardiac Autoimmunity，and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus [J]. Circulation，2019，139（6）：730-743. |
|
|
|
